National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Trastuzumab emtansine (Kadcyla®) is indicated as a single agent, for the adjuvant treatment of adults with HER2-positive, early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.


NCPE Assessment Process Complete
Rapid review commissioned 20/01/2020
Rapid review completed 27/02/2020
Rapid Review outcome A full HTA is recommended to assess the clinical and cost effectiveness of trastuzumab emtansine compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 04/03/2020
Pre-submission consultation with Applicant 31/03/2020
Current status Awaiting HTA submission from company